Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27137556 | 0.75 | RXRA (0.42) | ARPTGS2RXRAGRIN1GRIN2B | |
| SCHEMBL30847962 | 0.73 | GAA (0.32) | ARRXRAGRIN1GRIN2BMALT1 | |
| SCHEMBL27132542 | 0.73 | GAA (0.32) | ARRXRAGRIN1GRIN2BMALT1 | |
| SCHEMBL27137469 | 0.73 | RXRA (0.41) | ARPTGS2RXRAGRIN1GRIN2B | |
| SCHEMBL1338189 | 0.72 | MAPK1 (0.51) | PTGS2 | |
| SCHEMBL27137537 | 0.72 | AR (0.40) | ARPTGS2RXRAGRIN1GRIN2B | |
| SCHEMBL30847862 | 0.71 | AR (0.47) | ARRXRAGRIN1GRIN2BCYP17A1 | |
| SCHEMBL27137540 | 0.71 | AR (0.47) | ARRXRAGRIN1GRIN2BCYP17A1 | |
| SCHEMBL15454569 | 0.68 | SMARCA2 (0.46) | ARPTGS2SMARCA2SMARCA4DDR1 | |
| SCHEMBL30015071 | 0.68 | SMARCA2 (0.46) | ARPTGS2SMARCA2SMARCA4DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | AR 3413/4885PTGS2 2618/4885RXRA 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.